Swiss biopharmaceutical company AC Immune has received a third grant from the Michael J. Fox Foundation for the first human study of a PET tracer for Parkinson's disease. The amount of the grant was not disclosed.
The foundation first awarded AC Immune a research grant in 2015, which was extended in 2017. This further extension will support research for a potential alpha-synuclein PET tracer that would be developed with the company's proprietary Morphomer chemistry technology, it said.
The study will start in early 2019, according to AC Immune.
